



What is claimed is:


1. A compound of the Formula I



or a pharmaceutically acceptable salt thereof, wherein




is a 4-8 membered monocyclic or a 7-12 membered bicyclic ring containing 1 to 4 heteroatoms, selected from the group consisting of O, N or S; optionally saturated or unsaturated, optionally substituted with one or more substituent selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$ wherein m is 0-2 and R is hydroxy, alkoxy, alkyl or amino; with the proviso that that when Y^4 in formula I is H, the ring A may not be an oxazole, with X-Y containing side-chain connected at the carbon-2 as in




; The ring A may further contain a carboxamide, sulfone, sulfonamide or a acyl group,


A¹ is a 5-9 membered monocyclic or 7-14 membered polycyclic heterocycle of the formula



containing at least one nitrogen atom and optionally 1 to 4 heteroatoms or groups selected from O, N, S, SO₂ or CO; optionally saturated or unsaturated; optionally substituted by one or more R^k selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide and -COR wherein R is hydroxy, alkoxy, alkyl or amino;




include the following heterocyclic ring systems containing at least one nitrogen atom:




B2

or



B3


or



B4


wherein Z_a is H, alkyl, alkoxy, hydroxy, amine, alkylamine, dialkylamine, carboxyl, alkoxycarbonyl, hydroxyalkyl, halogen or haloalkyl and R^1 is H, alkyl, alkoxyalkyl, acyl, haloalkyl or alkoxycarbonyl, pyridylamino, imidazolylamino, morpholinopyridine, tetrahydronaphthylidine, oxazolylamino, thiazolylamino, pyrimidinylamino, quinoline, isoquinoline, tetrahydroquinoline, imidazopyridine, benzimidazole, pyridone or quinolone;

the following heteroaryls include the ring systems described above,




for the pyridyl derived heterocycle, the substituents X_4 and X_5 are selected from the group consisting of H, alkyl, branched alkyl, alkylamino, alkoxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano or acylamino groups; the substituents X_4 and X_5 can be methyl, methoxy, amine, methylamine, trifluoromethyl, dimethylamine, hydroxy, chloro, bromo, fluoro and cyano. X_6 may preferentially be H, alkyl, hydroxy, halogen, alkoxy and haloalkyl; the pyridyl ring can be fused with a 4 - 8 membered ring, optionally saturated or unsaturated wherein these ring systems include tetrahydronaphthyridine, quinoline, tetrahydroquinoline, azaquinoline, morpholinopyridine, imidazo-pyridine; the monocyclic ring systems such as imidazole, thiazole, oxazole, pyrazole, may


contain an amino or alkylamino substituent at any position within the ring; when Z_1 of Formula I is CO or SO₂, the linkage A¹-Z₂ of Formula I includes the heterocycle derived ring systems such as: pyridine, imidazole, thiazole, oxazole, benzimidazole, imidazopyridine; heterocycles for A¹-Z₂ may include




B = NH, O, S
R = H, Me




B = NH, O, S
R = H, Me




B = NH, O, S
R = H, Me




B = NH, O, S
R = H, Me




B = NH, O, S
R = H, Me




B = N, CH
R = H, Me



B = N, CH
R = H, Me




B = NH, O, S
R = H, Me



B = N, CH
R = H, Me

wherein X₄ is as defined above,

or A¹ is



wherein Y¹ is selected from the group consisting of N-R², O, and S;

R² is selected from the group consisting of H; alkyl; aryl; hydroxy; alkoxy; cyano; amido; alkylcarbonyl; arylcarbonyl; alkoxy carbonyl; aryloxy carbonyl; haloalkylcarbonyl; haloalkoxy carbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxy carbonyl;

R^2 taken together with R^7 forms a 4-12 membered dinitrogen containing heterocycle optionally substituted with one or more substituent selected from the group consisting of lower alkyl, thioalkyl, alkylamino, hydroxy, keto, alkoxy, halo, phenyl, amino, carboxyl or carboxyl ester;


- or R^2 taken together with R^7 forms a 4-12 membered heterocycle containing one or more heteroatom selected from O, N and S optionally unsaturated;
- or R^2 taken together with R^7 forms a 5 membered heteroaromatic ring fused with an aryl or a heteroaryl ring;

R^7 (when not taken together with R^2) and R^8 are independently selected from the group consisting of H; alkyl; aralkyl; amino; alkylamino; hydroxy; alkoxy; arylamino; amido, alkylcarbonyl, arylcarbonyl; alkoxycarbonyl; aryloxy; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl; cycloalkyl; bicycloalkyl; aryl; acyl; benzoyl;

- or NR^7 and R^8 taken together form a 4-12 membered mononitrogen containing monocyclic or bicyclic ring optionally substituted with one or more substituent selected from lower alkyl, carboxyl derivatives, aryl or hydroxy and wherein said ring optionally contains a heteroatom selected from the group consisting of O, N and S;

R^5 is selected from the group consisting of H and alkyl;

or



wherein Y^2 is selected from the group consisting of alkyl; cycloalkyl; bicycloalkyl; aryl; monocyclic heterocycles;

Z_1 is selected from the group consisting of CH_2 , O, CH_2O , NH, CO, S, SO, $CH(OH)$ and SO_2 ;

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatom selected from the group consisting of O, S and N; alternatively $Z_1 - Z_2$ may further contain a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, or acyl group;

wherein the carbon and nitrogen atoms of $Z_1 - Z_2$ are optionally substituted by alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl or acylamino;

Additionally, $Z_1 - Z_2$ may contain a 5- or 6-membered aryl or heteroaryl ring optionally substituted with R^c , wherein the heteroaryl ring may contain 1-3 heteroatoms selected from the group consisting of O, N and S;

X is selected from the group consisting of $-CHR^e-$, $-NR^f-$, $-O-$, $-S-$, $-SO_2-$, and $-CO-$ wherein R^e is H, lower alkyl, alkoxy, cycloalkyl, alkoxyalkyl, hydroxy, alkynyl, alkenyl, haloalkyl, thioalkyl or aryl; wherein when R^e is hydroxy, the hydroxy group can optionally form a lactone with the carboxylic acid function of the chain; wherein R^f is selected from the group consisting of H, alkyl, aryl, benzyl and haloalkyl;

Y is selected from the group consisting of $(CH_2)_p$, $-CHR^g-$, $-NR^g-$, CO and SO_2 , wherein R^g is selected from the group consisting of H, alkyl,


haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl; wherein p is 0 or 1;

optionally the group X-Y can contain a moiety selected from the group consisting of acyl, alkyl, sulfonyl, amino, ether, thioether, carboxamido, sulfonamido, aminosulfonyl and olefins;

Y^3 and Y^4 are independently selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne; wherein alkyl chain may be straight or branched and optionally containing one or more heteroatoms selected from the group consisting of N, O, and S, and may further contain a sulfone, sulfoamide, nitrile, carboxamide, carboalkoxy or carboxyl group; wherein aryl and heteroaryl rings may be monocyclic or bicyclic optionally containing 1-5 heteroatoms and wherein said ring may be saturated or unsaturated, and such rings may optionally be substituted by one or more substituent R^c ;

With the proviso that when Y^3 or Y^4 is H, Y^5 may be C or N, otherwise Y^5 is C;


or Y^3 taken together with Y^4 forms a 3-8 membered monocyclic or a 7-11 membered bicyclic ring B,



IA

optionally containing one or more double bonds, optionally containing one or more heteroatom or functional group selected from O, NR^g , S, CO or SO_2 , optionally substituted with one or more substituent selected from the group consisting of alkyl, haloalkyl, halogen, haloalkyl, alkoxy, alkyne, cyano, alkylsulfone, sulfonamide, carboalkoxy and carboxyalkyl;

or X taken together with Y^3 forms a 3-7 membered monocyclic ring C,



IB

optionally containing one or more double bonds, optionally containing one or more heteroatom or functional group selected from O, NR^g, S, CO or SO₂, optionally substituted with one or more substituent selected from the group consisting of alkyl, halogen, alkoxy, haloalkyl, hydroxyalkyl, or alkoxyalkyl;

R^b is X₂ - R^h wherein X₂ is selected from the group consisting of O, S and NRⁱ wherein R^h and Rⁱ are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl and alkoxyalkyl.

2. A compound according to claim 1, wherein

A¹, Z₁, Z₂, Y³, Y⁴ and ring A are defined as in claim 1;


X is of -CHR^e-, wherein R^e is H;

Y is -(CH₂)_p wherein p = 0;

Y⁵ is a carbon;


R^b is OH.

3. A compound according to Claim 2, wherein ring A





is selected from the group consisting of oxadiazole, thiazole, isooxazole, imidazole, pyrazole, thiadiazole, triazole, tetrazole, pyridine or pyrimidine.


4. A compound according to Claim 2, wherein Y3 or Y4 is independently selected from the the group consisting of:




$R_1 = \text{H, alkyl, OMe, OH, halogen, amino, CN}$




$X = \text{CH}_2, \text{O}$




$R_1 = \text{H, alkyl, OMe, OH, halogen, amino, CN}$



$R_1 = \text{H, alkyl, OMe, OH, halogen}$




$X = \text{NH, NMe, O, S}$




$\text{H, alkyl, CH}_2\text{B}_1\text{R}$ ($\text{B}_1 = \text{O, SO}_2, \text{S, CO}$; $\text{R} = \text{alkyl, aryl}$), CH_2OH , $\text{---}\equiv\text{R}$
 ($\text{R} = \text{alkyl, aryl, alkoxyalkyl}$)


5. A compound according to Claim 2, wherein A¹ is selected from the group consisting of




$X = \text{CH}_2, \text{O, S, SO}_2, \text{CO, CF}_2, \text{CMe}_2$
 $R = \text{H, Me, OMe, OH, NR}_2$




$X = \text{CH}_2, \text{O, S, SO}_2, \text{CO, CF}_2, \text{CMe}_2$
 $R = \text{H, Me, OMe, OH, NR}_2$






$X = \text{CH}_2, \text{O, S, SO}_2, \text{CO, CMe}_2$
 $R = \text{H, Me, OMe, OH}$




$X = \text{H, alkyl, acyl, alkoxyalkyl, haloalkyl}$
 $R = \text{H, Me, OH, OMe, NR}_2$



$R = \text{H, Me, NR}_2$
 OMe, OH




6. A compound according to claim 2, wherein ring A is selected from the group consisting of oxadiazole, thiazole or a pyridine.
7. A compound according to claim 6, wherein Y^3 or Y^4 is independently selected from the group consisting of




H, Me, Ph, Et, Pr, i-Pr, CH_2OCH_2Ph

8. A compound according to claim 6, wherein A^1 is



9. A compound according to claim 1, wherein

Y^3 taken together with Y^4 forms a 3-8 membered monocyclic or a 7-11 membered bicyclic ring B (formula IA),



IA

optionally containing one or more double bonds, optionally containing one or more heteroatom or functional group selected from O, NR^g , S, CO or SO_2 , optionally substituted with one or more substituent selected from the group consisting of alkyl, haloalkyl, halogen, haloalkyl, alkoxy, alkyne, cyano, alkylsulfone, sulfonamide,

carboalkoxy and carboxyalkyl; wherein R^9 is selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, and carboxyalkyl.

A^1 , Z_1 , Z_2 , and ring A are defined as in claim 1;


X is of $-CHR^e-$, wherein R^e is H ;

Y is $-(CH_2)_p$ wherein $p = 0$;


Y^5 is a carbon;

R^b is OH.


10. A compound according to claim 9, wherein ring A is an oxadiazole




11. A compound according to claim 10, wherein ring B is a five or six membered spiro system



12. A compound according to claim 11, wherein A^1 is



13. A compound according to claim 1, wherein
X taken together with Y³ forms a 3-7 membered monocyclic ring C
(formula IB),



optionally containing one or more double bonds, optionally containing one or more heteroatom or functional group selected from O, NR^g, S, CO or SO₂, optionally substituted with one or more substituent selected from the group consisting of alkyl, halogen, alkoxy, haloalkyl, hydroxyalkyl, or alkoxyalkyl; wherein R^g is selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, and carboxyalkyl;

A¹, Z₁, Z₂, Y⁴, and ring A are defined as in claim 1;


X is selected from the group consisting of -CR^e- wherein R^e is H, lower alkyl, alkoxy, cycloalkyl, alkoxyalkyl, hydroxy, alkynyl, alkenyl, haloalkyl, thioalkyl or aryl;

Y is -(CH₂)_p wherein p = 0 or 1;

Y⁵ is a carbon;

R^b is OH.

14. A compound according to claim 13, wherein ring A is an oxadiazole and ring C is a cyclopropyl ring (formula IC).



15. The method according to Claim 1 wherein the compound selected from the group consisting of

3-methyl-4-(3-{3-[(pyridin-2-ylamino)methyl]phenyl}-1,2,4-oxadiazol-5-yl)butanoic acid

3-methyl-4-(3-{4-[(pyridin-2-ylamino)methyl]phenyl}-1,2,4-oxadiazol-5-yl)butanoic acid

3,3-dimethyl-4-{4-[4-(pyridin-2-ylamino)butyl]-1,3-thiazol-2-yl}butanoic acid

[1-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}methyl)cyclopentyl]-acetic acid

4-phenyl-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}-butanoic acid

2-phenyl-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}-butanoic acid

3,3-dimethyl-4-{3-[2-(2-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)ethyl]-1,2,4-oxadiazol-5-yl}butanoic acid

[1-({3-[2-(2-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)ethyl]-1,2,4-oxadiazol-5-yl}methyl)cyclopentyl]acetic acid

4-{3-[2-(2-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)ethyl]-1,2,4-oxadiazol-5-yl}-4-phenylbutanoic acid

4-{3-[2-(2-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)ethyl]-1,2,4-oxadiazol-5-yl}-2-phenylbutanoic acid

4-{3-[2-(2-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)ethyl]-1,2,4-oxadiazol-5-yl}-2-phenylbutanoic acid

3,3-dimethyl-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-
 1,2,4-oxadiazol-5-yl}butanoic acid
 [1-({3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-
 oxadiazol-5-yl)methyl)cyclopentyl]acetic acid
 4-phenyl-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-
 1,2,4-oxadiazol-5-yl}butanoic acid
 2-phenyl-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-
 1,2,4-oxadiazol-5-yl}butanoic acid
 3-(1,3-benzodioxol-5-yl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-
 2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid
 3-(1,3-benzodioxol-5-yl)-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-
 oxadiazol-5-yl}butanoic acid
 3-quinolin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-
 propyl]-1,2,4-oxadiazol-5-yl}butanoic acid
 3-quinolin-3-yl 4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}-
 butanoic acid
 3-(3-methoxyphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
 yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid
 3-(3-methoxyphenyl)-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-
 oxadiazol-5-yl}butanoic acid
 3-(4-methoxyphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
 yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid
 3-(4-methoxyphenyl)-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-
 oxadiazol-5-yl}butanoic acid
 3-(3-fluorophenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
 yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid
 3-(3-fluorophenyl)-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-
 yl}butanoic acid
 3-(4-fluorophenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-
 propyl]-1,2,4-oxadiazol-5-yl}butanoic acid
 3-(4-fluorophenyl)-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-
 yl}butanoic acid
 4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-
 oxadiazol-5-yl}-3-[3-(trifluoromethyl)phenyl]butanoic acid

4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}-3-[3-(trifluoromethyl)-phenyl]butanoic acid

3-(3-hydroxyphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-(3-hydroxyphenyl)-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-pyridin-3-yl-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-phenyl-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-phenyl-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-methyl-3-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}-methyl)pentanoic acid

[1-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}methyl)-cyclohexyl]acetic acid

3-methyl-3-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}-methyl)-hexanoic acid

3,4-dimethyl-3-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}methyl)-pentanoic acid

3-ethyl-3-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}methyl)-pentanoic acid

4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-methyl-3-phenyl-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-yl}butanoic acid

3-Methyl-3-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-[1,2,4]oxadiazol-5-ylmethyl}-pentanoic acid

3-Methyl-3-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-[1,2,4]oxadiazol-5-ylmethyl}-hexanoic acid

3,4-Dimethyl-3-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-[1,2,4]oxadiazol-5-ylmethyl}-pentanoic acid

3-Ethyl-3-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-ylmethyl}-pentanoic acid
 3-Methyl-3-phenyl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-[1,2,4]oxadiazol-5-yl}-butyric acid
 3-Phenyl-3-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-ylmethyl}-pentanoic acid
 3-Phenyl-3-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-ylmethyl}-hexanoic acid
 4-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-[1,2,4]oxa-
 diazol-5-yl}-butyric acid
 3-Methyl-3-pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-
 2-yl)-propyl]-[1,2,4]oxadiazol-5-yl}-butyric acid
 (1-Acetyl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-ylmethyl}-piperidin-4-yl)-acetic acid
 (1-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)propyl]-
 [1,2,4]oxadiazol-5-ylmethyl}-cyclohexyl)-acetic acid
 3-Methyl-3-pyridin-3-yl-4-{3-[4-(pyridin-2-ylamino)butyl]-
 [1,2,4]oxadiazol-5-yl}-butyric acid
 4-(benzyloxy)-3-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-
 yl)methyl)-butanoic acid
 4-[4-(N-pyridin-2-yl-beta-alanyl)piperazin-1-yl]butanoic acid
 4-{4-[3-(pyridin-2-ylamino)propyl]piperazin-1-yl}butanoic acid
 2-methyl-6-[3(2-pyridylamino)propoxy]-3-pyridinebutanoic acid
 β,β -dimethyl-3-[5-(2-pyridinylamino)pentyl]-1,2,4-oxadiazole-5-
 butanoic acid
 β,β -dimethyl-3-[4-(2-pyridinylamino)butyl]-1,2,4-oxadiazole-5-
 butanoic acid
 β,β -dimethyl-3-[[[2-(2-pyridinylamino)ethyl]thio]methyl]-1,2,4-
 oxadiazole-5-butanoic acid
 4-Carboxymethyl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-[1,2,4]oxadiazol-5-ylmethyl}-piperidine-1-carboxylic acid tert-
 butyl ester

(1-Benzoyl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-ylmethyl}-piperidin-4-yl)-acetic acid
 [4-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-ylmethyl}-1-(2,2,2-trifluoroacetyl)-piperidin-4-yl]-
 acetic acid
 4-(phenylthio)-3-({3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-
 yl)methyl}butanoic acid
 4-(phenylthio)-3-({3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
 yl)propyl]-1,2,4-oxadiazol-5-yl)methyl}butanoic acid
 3-methyl-4-{3-[4-(pyridin-2-ylamino)butyl]-1,2,4-oxadiazol-5-
 yl}butanoic acid hydrochloride
 3-methyl-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-
 1,2,4-oxadiazol-5-yl}butanoic acid
 ((1S,2R)-2-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-
 1,2,4-oxadiazol-5-yl}cyclopropyl)acetic acid
 ((1S,2S)-2-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-
 1,2,4-oxadiazol-5-yl}cyclopropyl)acetic acid
 3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-4H-[1,2,4]triazol-3-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-
 2-yl)-propyl]-tetrazol-2-yl}-butyric acid
 (2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-[1,3,4]oxa-
 diazol-2-yl}-cyclopropyl)-acetic acid
 3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,3,4]oxadiazol-2-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-[1,3,4]oxadiazol-2-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-
 yl)-propyl]-[1,3,4]oxadiazol-2-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-
 2-yl)-propyl]-[1,3,4]oxadiazol-2-yl}-butyric acid
 (2-{2-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-2H-
 tetrazol-5-yl}-cyclopropyl)-acetic acid

3-Phenyl-4-{2-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 2H-tetrazol-5-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{2-[3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-2H-tetrazol-5-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{2-[3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-2H-tetrazol-5-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{2-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-
 yl)-propyl]-2H-tetrazol-5-yl}-butyric acid
 3-Pyridin-3-yl-4-{2-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-2H-tetrazol-5-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{2-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-
 2-yl)-propyl]-2H-tetrazol-5-yl}-butyric acid
 (2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-
 yl}-cyclopropyl)-acetic acid
 3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 isoxazol-3-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-
 yl)-propyl]-isoxazol-3-yl}-butyric acid
 3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-isoxazol-3-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-
 2-yl)-propyl]-isoxazol-3-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-
 yl)-propyl]-isoxazol-5-yl}-butyric acid
 3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-isoxazol-5-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-
 2-yl)-propyl]-isoxazol-5-yl}-butyric acid
 3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 1H-pyrazol-3-yl}-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid
 3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid
 (2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid
 (2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-cyclopropyl)-acetic acid
 (2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid
 3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-Phenyl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid

3-Phenyl-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid

3-Pyridin-3-yl-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid

3-Phenyl-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-imidazol-1-yl]-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-[4-(3-5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl-propionyl)-imidazol-1-yl]-butyric acid
 3-(3-Fluoro-phenyl)-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-
 propionyl)-imidazol-1-yl]-butyric acid
 3-Pyridin-3-yl-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-
 propionyl)-imidazol-1-yl]-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-
 yl-propionyl)-imidazol-1-yl]-butyric acid
 4-{4-[1-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 imidazol-1-yl}-3-phenyl-butyl-butiric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[1-hydroxy-3-(5,6,7,8-
 tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{4-[1-hydroxy-3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid
 4-{4-[1-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 imidazol-1-yl}-3-pyridin-3-yl-butyl-butiric acid
 4-{4-[1-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 imidazol-1-yl}-3-pyridin-3-yl-butyl-butiric acid
 4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-
 ynyl]-imidazol-1-yl}-3-phenyl-butyl-butiric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-hydroxy-3-(5,6,7,8-
 tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-imidazol-1-yl}-butyric
 acid
 3-(3-Fluoro-phenyl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-prop-1-ynyl]-imidazol-1-yl}-butyric acid
 4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-
 ynyl]-imidazol-1-yl}-3-pyridin-3-yl-butyl-butiric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{2-[3-(5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-2H-tetrazol-5-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{2-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-
 yl)-propyl]-2H-tetrazol-5-yl}-butyric acid
 3-Pyridin-3-yl-4-{2-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-2H-tetrazol-5-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{2-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-2H-tetrazol-5-yl}-butyric acid

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-butyric acid

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-1H-pyrazol-3-yl}-cyclopropyl)-acetic acid
 (2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid
 3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid
 3-Phenyl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid
 3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid
 3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid
 3-Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid
 3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid
 3-Phenyl-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid
 3-Pyridin-3-yl-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-2H-pyrazol-3-yl}-butyric acid
 3-Phenyl-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-imidazol-1-yl]-butyric acid
 3-(2,3-Dihydro-benzofuran-6-yl)-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-imidazol-1-yl]-butyric acid
 3-(3-Fluoro-phenyl)-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-imidazol-1-yl]-butyric acid
 3-Pyridin-3-yl-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-imidazol-1-yl]-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-[4-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-imidazol-1-yl]-butyric acid
 4-{4-[1-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-3-phenyl-butylric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[1-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{4-[1-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

4-{4-[1-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-3-pyridin-3-yl-butyl butyric acid

4-{4-[1-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-3-pyridin-3-yl-butyl butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-imidazol-1-yl}-3-phenyl-butyl butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-imidazol-1-yl}-butyl butyric acid

3-(3-Fluoro-phenyl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-imidazol-1-yl}-butyl butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-imidazol-1-yl}-3-pyridin-3-yl-butyl butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-imidazol-1-yl}-butyl butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-pyrazol-1-yl}-3-phenyl-butyl butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-pyrazol-1-yl}-butyl butyric acid

3-(3-Fluoro-phenyl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-pyrazol-1-yl}-butyl butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-pyrazol-1-yl}-3-pyridin-3-yl-butyl butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-pyrazol-1-yl}-butyl butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-pyrazol-1-yl}-3-phenyl-butyl butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-prop-1-ynyl]-pyrazol-1-yl}-butyl butyric acid

acid-3-(3-Fluoro-phenyl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-pyrazol-1-yl}-butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-pyrazol-1-yl}-3-pyridin-3-yl-butyl butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-pyrazol-1-yl}-butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-pyrazol-1-yl}-butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-imidazol-1-yl}-3-phenyl-butyl butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-imidazol-1-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-imidazol-1-yl}-butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-imidazol-1-yl}-3-pyridin-3-yl-butyl butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propenyl]-imidazol-1-yl}-butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-3-phenyl-butyl butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-3-pyridin-3-yl-butyl butyric acid

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-imidazol-1-yl}-butyric acid

4-{4-[3-Hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-3-phenyl-butyl butyric acid

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid

3-(3-Fluoro-phenyl)-4-{4-[3-hydroxy-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-pyrazol-1-yl}-butyric acid

363

3-(3-Fluoro-phenyl)-4-{3-[4-(3*H*-imidazol-4-ylamino)-butyl]-
 [1,2,4]oxadiazol-5-yl}-butyric acid
 3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(6-methylamino-pyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-yl}-butyric acid
 3-(3-Fluoro-phenyl)-4-{3-[3-(6-methylamino-pyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-yl}-butyric acid
 4-{3-[3-(6-Ethylamino-pyridin-2-yl)-
 propyl]-[1,2,4]oxadiazol-5-yl}-3-(3-fluoro-phenyl)-butyric acid
 3-(3-Fluoro-phenyl)-4-(3-{3-[6-(2-methoxy-ethylamino)-pyridin-2-yl]-
 propyl}-[1,2,4]oxadiazol-5-yl)-butyric acid
 3-(3-Fluoro-phenyl)-4-(3-{3-[6-(3-methoxy-propylamino)-pyridin-2-yl]-
 propyl}-[1,2,4]oxadiazol-5-yl)-butyric acid
 3-(3-Fluoro-phenyl)-4-(3-{3-[6-(2,2,2-trifluoro-ethylamino)-pyridin-2-
 yl]-propyl}-[1,2,4]oxadiazol-5-yl)-butyric acid
 3-(3-Fluoro-phenyl)-4-{3-[3-(5-oxo-5,6,7,8-tetrahydro-
 [1,8]naphthyridin-2-yl)-propyl]-[1,2,4]oxadiazol-5-yl}-butyric acid
 4-{3-[3-(5,5-Dimethyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-
 propyl]-[1,2,4]oxadiazol-5-yl}-3-(3-fluoro-phenyl)-butyric acid
 4-{3-[3-(5,5-Difluoro-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-
 [1,2,4]oxadiazol-5-yl}-3-(3-fluoro-phenyl)-butyric acid
 3-(1,3-benzodioxol-5-yl)-4-{3-[(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
 ylmethoxy)methyl]-1,2,4-oxadiazol-5-yl}butanoic acid.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 2-15 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Claim 1 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

19. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Claims 2-18^{RAP 6/15/01} and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.
20. A method for treating conditions mediated by the $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound of Claim 1.
21. A method for treating conditions mediated by the $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound of Claims 2-18^{RAP 6/15/01}.
22. The method according to Claim 16 wherein the condition treated is tumor metastasis.
23. The method according to Claim 17 wherein the condition treated is tumor metastasis.
24. The method according to Claim 18 wherein the condition treated is tumor metastasis.
25. The method according to Claim 20 wherein the condition treated is tumor metastasis.
26. The method according to Claim 16 wherein the condition treated is solid tumor growth.
27. The method according to Claim 17 wherein the condition treated is solid tumor growth.
28. The method according to Claim 18 wherein the condition treated is solid tumor growth.

29. The method according to Claim 20 wherein the condition treated is solid tumor growth.
30. The method according to Claim 16 wherein the condition treated is angiogenesis.
31. The method according to Claim 17 wherein the condition treated is angiogenesis.
32. The method according to Claim 18 wherein the condition treated is angiogenesis.
33. The method according to Claim 20 wherein the condition treated is angiogenesis.
34. The method according to Claim 16 wherein the condition treated is osteoporosis.
35. The method according to Claim 17 wherein the condition treated is osteoporosis.
36. The method according to Claim 20 wherein the condition treated is osteoporosis.
37. The method according to Claim 21 wherein the condition treated is osteoporosis.
38. The method according to Claim 16 wherein the condition treated is humoral hypercalcemia of malignancy.
39. The method according to Claim 17 wherein the condition treated is humoral hypercalcemia of malignancy.

40. The method according to Claim 20 wherein the condition treated is humoral hypercalcemia of malignancy.
41. The method according to Claim 21 wherein the condition treated is humoral hypercalcemia of malignancy.
42. The method according to Claim 16 wherein the condition treated is smooth muscle cell migration.
43. The method according to Claim 17 wherein the condition treated is smooth muscle cell migration.
44. The method according to Claim 20 wherein the condition treated is smooth muscle cell migration.
45. The method according to Claim 21 wherein the condition treated is smooth muscle cell migration.
46. The method according to Claim 16 wherein restenosis is inhibited.
47. The method according to Claim 17 wherein restenosis is inhibited.
48. The method according to Claim 20 wherein restenosis is inhibited.
49. The method according to Claim 21 wherein restenosis is inhibited.
50. The method according to Claim 16 wherein atherosclerosis is inhibited.
51. The method according to Claim 17 wherein atherosclerosis is inhibited.

52. The method according to Claim 20 wherein atherosclerosis is inhibited.
53. The method according to Claim 21 wherein atherosclerosis is inhibited.
54. The method according to Claim 16 wherein macular degeneration is inhibited.
55. The method according to Claim 17 wherein macular degeneration is inhibited.
56. The method according to Claim 20 wherein macular degeneration is inhibited.
57. The method according to Claim 21 wherein macular degeneration is inhibited.
58. The method according to Claim 16 wherein retinopathy is inhibited.
59. The method according to Claim 17 wherein retinopathy is inhibited.
60. The method according to Claim 20 wherein retinopathy is inhibited.
61. The method according to Claim 21 wherein retinopathy is inhibited.
62. The method according to Claim 16 wherein arthritis is inhibited.
63. The method according to Claim 17 wherein arthritis is inhibited.
64. The method according to Claim 20 wherein arthritis is inhibited.
65. The method according to Claim 21 wherein arthritis is inhibited.

66. A method of preventing inflammatory infiltrates in a patient in need of an $\alpha_v\beta_3$ antagonist comprising administering to said patient an effective amount of an $\alpha_v\beta_3$ antagonist wherein said antagonist selectively inhibits $\alpha_v\beta_3$ over β_6 integrin.
67. A method of preventing inflammatory infiltrates in a patient in need of an $\alpha_v\beta_5$ antagonist comprising administering to said patient an effective amount of an $\alpha_v\beta_5$ antagonist wherein said antagonist selectively inhibits $\alpha_v\beta_5$ over β_6 integrin.
68. A method of preventing inflammatory infiltrates in a patient in need of a mixed or dual $\alpha_v\beta_3/\alpha_v\beta_5$ antagonists comprising administering to said patient an effective amount of mixed or dual $\alpha_v\beta_3/\alpha_v\beta_5$ antagonist wherein said antagonist selectively inhibits $\alpha_v\beta_3$ and $\alpha_v\beta_5$ over β_6 integrin.
69. A $\alpha_v\beta_3$ antagonist wherein said $\alpha_v\beta_3$ antagonist is selective over $\alpha_v\beta_8$.
70. A a mixed or dual $\alpha_v\beta_3/\alpha_v\beta_5$ antagonist wherein said $\alpha_v\beta_3$ antagonist is selective over $\alpha_v\beta_8$.

add
A.